Ken Setchell, PhD, director, Mass Spectrometry Lab, recently received the MSACL (Mass Spectrometry Applications to the Clinical Lab) Distinguished Contribution Award 2016. Setchell was recognized for discovering genetic defects in bile acid synthesis and developing the first new bile acid therapy for cholestatic liver disease to be approved in 40 years. He was nominated by his peers and honored at the International MSACL 2016 Congress in Palm Springs. Following the award presentation, he delivered a plenary lecture on his research.